These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 20556613)

  • 1. Lack of effect of casopitant on the pharmacokinetics of docetaxel in patients with cancer.
    Dandamudi UB; Adams LM; Johnson B; Bauman J; Morris S; Murray S; Webb RT; Gartner E; Hohl R; Lewis LD
    Cancer Chemother Pharmacol; 2011 Apr; 67(4):783-90. PubMed ID: 20556613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of ondansetron and dexamethasone.
    Johnson B; Adams L; Lu E; Zhang K; Lebowitz P; Lates C; Blum R
    Support Care Cancer; 2009 Sep; 17(9):1177-85. PubMed ID: 19205755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ketoconazole and rifampin significantly affect the pharmacokinetics, but not the safety or QTc interval, of casopitant, a neurokinin-1 receptor antagonist.
    Johnson BM; Adams LM; Zhang K; Gainer SD; Kirby LC; Blum RA; Apseloff G; Morrison RA; Schutz RA; Lebowitz PF
    J Clin Pharmacol; 2010 Aug; 50(8):951-9. PubMed ID: 20124517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients.
    Nygren P; Hande K; Petty KJ; Fedgchin M; van Dyck K; Majumdar A; Panebianco D; de Smet M; Ahmed T; Murphy MG; Gottesdiener KM; Cocquyt V; van Belle S
    Cancer Chemother Pharmacol; 2005 Jun; 55(6):609-16. PubMed ID: 15723220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial.
    Grunberg SM; Rolski J; Strausz J; Aziz Z; Lane S; Russo MW; Wissel P; Guckert M; Wright O; Herrstedt J
    Lancet Oncol; 2009 Jun; 10(6):549-58. PubMed ID: 19428297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of casopitant, a novel NK-1 receptor antagonist, on the pharmacokinetics and pharmacodynamics of steady-state warfarin.
    Kirby LC; Johnson BM; Adams LM; Eberwein DJ; Zhang K; Murray SC; Lates CD; Blum RA; Morris SR
    J Clin Pharmacol; 2010 May; 50(5):566-75. PubMed ID: 20220045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase 2 trial results with the novel neurokinin-1 receptor antagonist casopitant in combination with ondansetron and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving moderately emetogenic chemotherapy.
    Arpornwirat W; Albert I; Hansen VL; Levin J; Bandekar RR; Grunberg SM
    Cancer; 2009 Dec; 115(24):5807-16. PubMed ID: 19834961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of aprepitant, a moderate CYP3A4 inhibitor, on bosutinib exposure in healthy subjects.
    Hsyu PH; Pignataro DS; Matschke K
    Eur J Clin Pharmacol; 2017 Jan; 73(1):49-56. PubMed ID: 27718000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An open-label, randomized, single-center, two-period, phase I, crossover study of the effect of zibotentan (ZD4054) on the pharmacokinetics of midazolam in healthy male volunteers.
    Tomkinson HK; Kemp JV; Wollseifen T; Morris T; Oliver SD
    Clin Ther; 2010 Jul; 32(7):1372-86. PubMed ID: 20678684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of hepatic or renal impairment on the pharmacokinetics of casopitant, a NK-1 receptor antagonist.
    Bauman JW; Antal JM; Adams LM; Johnson BM; Murray SC; Peng B; Kirby LC; Lebowitz PF; Marbury TC; Swan S; Gutierrez M
    Invest New Drugs; 2012 Apr; 30(2):662-71. PubMed ID: 21188466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of single and repeat doses of casopitant on the pharmacokinetics of CYP450 3A4 substrates midazolam and nifedipine.
    Zamuner S; Johnson BM; Pagliarusco S; Fina P; Peroni M; Fiore M; Adams LM; Fernandes SA
    Br J Clin Pharmacol; 2010 Oct; 70(4):537-46. PubMed ID: 20840445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase III trial of casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy.
    Herrstedt J; Apornwirat W; Shaharyar A; Aziz Z; Roila F; Van Belle S; Russo MW; Levin J; Ranganathan S; Guckert M; Grunberg SM
    J Clin Oncol; 2009 Nov; 27(32):5363-9. PubMed ID: 19805683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Casopitant: in vitro data and SimCyp simulation to predict in vivo metabolic interactions involving cytochrome P450 3A4.
    Motta P; Pons N; Pagliarusco S; Pellegatti M; Bonomo F
    Drug Metab Dispos; 2011 Mar; 39(3):363-72. PubMed ID: 21149541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Double-blind crossover study to assess potential differences in cytochrome P450 3A4 activity in healthy subjects receiving ondansetron plus dexamethasone, with and without aprepitant.
    Stoch SA; Gargano C; Valentine J; Braun MP; Murphy MG; Fedgchin M; Majumdar A; Pequignot E; Gottesdiener KM; Petty KJ; Panebianco D; Dean D; Kraft WK; Greenberg HE
    Cancer Chemother Pharmacol; 2011 Jun; 67(6):1313-21. PubMed ID: 20734049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NCT01110291: induction of CYP3A activity and lowered exposure to docetaxel in patients with primary breast cancer.
    Hilli J; Sailas L; Jyrkkiö S; Pyrhönen S; Laine K
    Cancer Chemother Pharmacol; 2011 Jun; 67(6):1353-62. PubMed ID: 20798939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of dolasetron and granisetron.
    Adams LM; Johnson B; Zhang K; Yue L; Kirby LC; Lebowitz P; Stoltz R
    Support Care Cancer; 2009 Sep; 17(9):1187-93. PubMed ID: 19205754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The influence of granisetron on the pharmacokinetics and pharmacodynamics of docetaxel in Asian lung cancer patients.
    Miyata M; Yasuda K; Burioka N; Takane H; Suyama H; Shigeoka Y; Endo M; Kurai J; Morita M; Igishi T; Shimizu E
    Cancer J; 2006; 12(1):69-72. PubMed ID: 16613665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The evaluation of drug rechallenge: the casopitant Phase III program.
    Hunt CM; Papay JI; Rich DS; Abissi CJ; Russo MW
    Regul Toxicol Pharmacol; 2010 Dec; 58(3):539-43. PubMed ID: 20932869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel.
    Engels FK; Ten Tije AJ; Baker SD; Lee CK; Loos WJ; Vulto AG; Verweij J; Sparreboom A
    Clin Pharmacol Ther; 2004 May; 75(5):448-54. PubMed ID: 15116057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aprepitant when added to a standard antiemetic regimen consisting of ondansetron and dexamethasone does not affect vinorelbine pharmacokinetics in cancer patients.
    Loos WJ; de Wit R; Freedman SJ; Van Dyck K; Gambale JJ; Li S; Murphy GM; van Noort C; de Bruijn P; Verweij J
    Cancer Chemother Pharmacol; 2007 Feb; 59(3):407-12. PubMed ID: 17051369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.